Edmund Harrington
Novartis (Switzerland)(CH)
Publications by Year
Research Areas
Multiple Myeloma Research and Treatments, Protein Degradation and Inhibitors, Chemical Synthesis and Analysis, Monoclonal and Polyclonal Antibodies Research, Chromatin Remodeling and Cancer
Most-Cited Works
- → Selective VPS34 inhibitor blocks autophagy and uncovers a role for NCOA4 in ferritin degradation and iron homeostasis in vivo(2014)724 cited
- → Discovery of VX-509 (Decernotinib): A Potent and Selective Janus Kinase 3 Inhibitor for the Treatment of Autoimmune Diseases(2015)87 cited
- → The Discovery of VX-745: A Novel and Selective p38α Kinase Inhibitor(2011)83 cited
- → Bile acid analogues are activators of pyrin inflammasome(2019)59 cited
- → Potent, Selective, and Orally Bioavailable Inhibitors of VPS34 Provide Chemical Tools to Modulate Autophagy in Vivo(2015)51 cited
- → Structure-based design and parallel synthesis of N-benzyl isatin oximes as JNK3 MAP kinase inhibitors(2009)45 cited
- → BRD9 degraders as chemosensitizers in acute leukemia and multiple myeloma(2022)43 cited
- → Identification of a novel NAMPT inhibitor by CRISPR/Cas9 chemogenomic profiling in mammalian cells(2017)39 cited
- → Small molecule Toll-like receptor 7 agonists localize to the MHC class II loading compartment of human plasmacytoid dendritic cells(2011)34 cited
- → Discovery and SAR of novel 4-thiazolyl-2-phenylaminopyrimidines as potent inhibitors of spleen tyrosine kinase (SYK)(2008)28 cited